europass

Curriculum Vitae

Personal information

Name	**Federica De Galitiis**
Professional address	**Istituto Dermopatico dell'Immacolata IDI-IRCCS** Via Monti di Creta, 104 - 00167 Rome (Italy)
Phone	+39 06 6646 3393
E-mail	f.degalitiis@idi.it degalitiis@yahoo.it
Date of birth	12/01/1970
Nationality	Italian

Profession **Medical Oncologist**

Work experience

March 2018 - present: **Medical Director and Chief** of the UOC Oncology, IDI-IRCCS, Rome

2017 - present: Registration to the Order of Experts and Collaborators of **Agenas** in the Clinical / Organizational / Epidemiological / Social Area

Nov 2016: **Professor at the II Level Master of Immuno-oncology** at the La Sapienza University, Rome

Dec 2012 - Oct 2013: **Medical Director** at the Oncology Department, ASL of Teramo, Giulianova and Sant'Omero hospital

Sept 2011: **Scientific consultant for Bristol-Myers Squibb S.r.l.** with participation at the training on Melanoma for Medical Scientific Representatives

2009 - April 2015: **Consultant** at the General Surgery Department, San Carlo di Nancy hospital, Rome

Aug 2006 - present: Full time **Medical Director** at the UOC Oncology, IDI-IRCCS, Rome

July 2005 - March 2006: **Medical Director** at the Oncology Department, ASL of Teramo, Giulianova and Sant'Omero hospital

Dec 2003 - Dec 2005: **Medical assistance activities** as On-Call Doctor and as Substitute for General Practitioners at the Sanatrix Affiliated Clinic, L'Aquila

Jan 2003 - June 2005: **Medical assistance activities** at the CUS L'Aquila Rugby Society and at the Italian Federation of the Regional Rugby Committee

2002 - 2003: **Technical / scientific collaboration contract** at the Department of Experimental Medicine, University of L'Aquila

Education	March 2021: First training ICH-GOOD CLINICAL PRACTICE (GCP) April 2019: Training course “Campus in Oncology”, Capri (NA) June 2015: II Level Master in Management of Health Services (MAS), LUISS April 2006: PhD in Experimental Medicine and Endocrinology, “Genetic alterations of clinical relevance in sporadic and hereditary colorectal cancer” 1998 - 2002: Post-graduate Specialization in Oncology, University of L'Aquila, “Determination of p53 gene mutations by FAMA in colorectal neoplasms. Prognostic evaluations" 1998 Degree in Medicine and Surgery, 108/110, University of L'Aquila, "Molecular Mechanism of Action of Mitoxantrone in Solid Neoplasms" 1988 Classical High School diploma at the Liceo Classico, Luigi Illuminati, Atri (TE)
Mother tongue	Italian
Other languages	English and French
Further information	**Participation in National Research Projects (MIUR):** - 2001: Family cancer of the breast and ovary. Multicenter study on biological and clinical characteristics and on the management of subjects at risk - Development of diagnostic-molecular strategies for the recognition of structural inactivation of the BRCA1 and BRCA2 genes and of chemoprevention programs in women with a genetic predisposition to breast cancer - 2003: Hereditary tumors of the breast: genetic studies and proteome analysis - Identification and clinical management of families with BRCA1 / BRCA2 genetic predisposition and molecular characterization of proliferative pathologies in carriers - 2004: Biomolecular characterization of breast carcinoma for the development of innovative systemic primary therapies - Characterization of the p53 genotype and gene expression profiles in breast cancer for the development of individual systemic primary therapies

Scientific publications

Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors
Morelli M, et al, Frontiers in Immunology. 2024 Mar 01;15:1346687

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center
Falcone R, et al. Curr Oncol. 2024 Jan 22;31(1):588-597

The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
Mezi S, et al. Cancers (Basel). 2023 Sep 15;15(18):4587

Italian nivolumab Expanded Access Program in melanoma adjuvant setting: patient outcomes and safety profile
Ascierto PA, et al. Eur J Cancer. 2023 Sep;191:113246

Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S, et al. J Pers Med. 2023 Feb 26;13(3):415

Cross-Cultural Adaptation and Preliminary Validation of Upper Limb Lymphedema Quality of Life Questionnaire (ULL-27) in Italian Female Patients with Breast Cancer-Related Lymphedema
Samela T, et al. Lymphat Res Biol. 2022 Dec;20(6):651-658

KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, et al. Lancet Oncol. 2022 Nov;23(11):1378-1388

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, et al. Eur J Cancer. 2022 Nov;176:207-217

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients
Verkhovskaia S, et al. J Cancer Res Clin Oncol. 2022 Sep;148(9):2529-2538

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
Levati L, et al. Cancers (Basel). 2022 Jul 29;14(15):3706

Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma"
Baggi A, et al. Eur J Cancer. 2022 May;166:309-310

KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, et al. Lancet. 2022 Apr 30;399(10336):1718-1729

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML, et al. Sci Rep. 2022 Mar 31;12(1):5448

Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR, et al. Clin Oncol. 2022 Jan;34(1):e18-e24

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A, et al. Clin Colorectal Cancer. 2021 Dec;20(4):318-325

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A, et al. Eur J Cancer. 2021 Nov;157:250-258

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S, et al. J Cancer Res Clin Oncol. 2021 Sep. doi: 10.1007/s00432-021-03811-3. Epub ahead of print.

The role of opioids in cancer response to immunotherapy.
Botticelli A, et al. J Transl Med. 2021 Mar 23;19(1):119

The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.
Fania L, et al. Recenti Prog Med. 2020 Dec;111(12):749-760

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG, et al. Front Immunol. 2020 Sep 25;11:579894

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O, et al. Eur J Cancer. 2020 Jul;134:19-28

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A, et al. Vaccines (Basel). 2020 Apr 28;8(2):203

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Cortellini A, et al. Eur J Cancer. 2020 Mar;128:17-26

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Cortellini A, et al. Oncoimmunology. 2020 Jan 7;9(1):1710389

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
Cortellini A, et al. J Transl Med. 2019 Nov 15;17(1):376

Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms.
Scoppola A, et al. Front Endocrinol (Lausanne). 2019 Nov 5;10:757

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A, et al. J Immunother Cancer. 2019 Feb 27;7(1):57

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A, et al. Oncologist. 2019 Feb 22

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP, et al. Cancer Immunol Immunother. 2019 Jan;68(1):97-107

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.
Queirolo P, et al. Eur J Cancer. 2018 Jul;97:59-61

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, et al. Front Immunol. 2017 Apr 12;8:386

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Ferrucci PF, et al. Br J Cancer. 2015 Jun 9;112(12):1904-10

Appropriatezza e costi del follow-up nelle pazienti con carcinoma della mammella.
De Galitiis F. Mondo Sanitario, 2016

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access program in Italy.
Chiarion-Sileni V, et al. Br J Cancer. 2014 Apr 1;110(7):1721-6

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M, et al. Eur J Cancer. 2014 Jan;50(1):121-7

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M, et al. Ann Oncol. 2013 Nov;24(11):2911-5

“Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G, et al. BMC Cancer. 2010 Oct 19;10:567

Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Morelli MF, et al. Oncol Rep. 2010 Jun;23(6):1635-40.

Novel P53 mutations detected by FAMA in colorectal cancers
De Galitiis F, et al. Ann Oncol. 2006 Jun;17 Suppl 7:vii78-vii83

Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficorella C, et al. Oncol Rep. 2006 May;15(5):1345-50

Timed flat infusion of 5-Fluoroutacil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose finding study
Ficorella C, et al. Br J Cancer. 2004 Aug 16;91(4):618-20

Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?
Ricevuto E, et al. Ficorella Tumori. 2003 Jul-Aug;89(4 Suppl):197-9

Prognostic value of p53 molecular status in high-risk primary breast cancer
Marchetti P, et al. Annals of Oncology 2003 May; Vol 14: 704-708

P16 hypermethylation contributes to the characterization of gene inactivaction profiles in primary gastric cancer
C Ficorella, et al. Oncology Reports 2003 Jan-Feb; Vol.10(1):169-73

Familiarity and heredity of tumors in function of an early surgical therapeutic approach
Ricevuto E, et al. Suppl Tumori. 2002 May-Jun;1(3):S89-91

Significato prognostico e predittivo delle alterazioni genetiche nel carcinoma gastrico
Ficorella C, et al. Minerva Medica, 1991, Suppl. 1, N1/2: 48-50, 2000

Terapia adiuvante nel carcinoma del colon retto in età geriatrica
Ficorella C, et al. Minerva Medica, 1990: 232-3; 19

Congresses and Courses as Speaker or Professor

28/02/2023 Editorial board member “SETTING NEXT HORIZON”, Rome

25/11/2022 Speaker at the meeting “Aiom: Best of the year 2022”, Rome

09/12/2019 Professor at the meeting “Difficult cases in immuno-oncology”, Rome

05/04/2019 Professor at the course “NIVOLUTION – Live around”, Rome

23/11/2018 Speaker at the Course “PROMETEO - project melanoma immunological therapy”, Rome

04/11/2018 Speaker at the “XXIV national congress IMI”, Bari

18/05/2018 Speaker at the meeting "NEXT 2018-WHO pNEN project and in clinical cases", Rome

07/07/2016 Professor at the course “Melanoma Life / Live”, Rome

30/09/2016 Speaker at the Course “Immuno-Oncology in the treatment of cancer: Innovation, Access and Sustainability”, Rome

02/24/2016 Speaker at the Conference: Oligometastatic disease. Past, Present and Future, Rome

19/06/2014 Speaker at the Seminar of Immuno.-Oncology: the new frontier of cancer therapy, Bari

12/06/2014 Speaker at the Course “MAME: Management of Metastatic Melanoma”

11/05/2012 Speaker at the Conference “Metastatic Breast cancer”, Bologna

29/06/2006 Speaker at the Course “The treatment of hormone-sensitive breast cancer: a changing scenario”

06/2006 Speaker at the VIII GOIM Conference “From Biomolecular and Technological Innovations to Clinical Application”, Messina

I authorize the treatment of personal data contained in my CV according to the current Italian directives (art.13 of D. Lgs. 196/2003 and art.13 GDPR 679/16)